| Value | ₹16,982 Cr |
|---|
NSE filing, NSE: GLENMARK. Summary written from the filing by ALFA Finder's alert engine.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,481.80
- Market cap
- ₹70,043 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 39.0×Sector 37.9×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 21.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue Rs 42,473 Mn, down 29.8% YoY on a reported basis. EBITDA Rs 8,638 Mn (20.3% margin); Adj PAT Rs 4,852 Mn (11.4% margin). North America headline is flattered by ISB 2001 licensing income.
Glenmark Pharmaceuticals Results Update
Glenmark Pharmaceuticals released its Q2 FY27 press release and MD&A for the quarter ended September 2026. Highlights show India growth and lower North America revenue.
Glenmark Pharmaceuticals Q2 FY27 Results: Net Profit ₹263.8 Cr, Down 56.8% YoY
Glenmark Pharmaceuticals Ltd reported revenue from operations of ₹4,247 Cr (-29.8% YoY) and net profit of ₹263.8 Cr (-56.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹263.8 Cr · -56.8% YoY
Glenmark Pharmaceuticals Other Announcement
Glenmark's partner IGI will present updated Phase 1 clinical data for ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma at the 68th ASH Annual Meeting. The presentation is scheduled for December 12, 2026.
Glenmark Pharmaceuticals Board Meeting Date
Glenmark Pharmaceuticals notified BSE of a board meeting on 05 Nov 2026 to consider unaudited Q2 FY27 results. No financial figures are disclosed in this advance intimation.
Glenmark Pharmaceuticals Other Announcement
Glenmark Pharmaceuticals has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI Regulation 31(1)(b).
Other results update announcements
All →Sula Vineyards Results Update
Sula Vineyards reported Q2 FY27 net profit up 34% YoY to Rs 8.1 Crore. The release also flags a fourth hotel and upcoming product launches.
Britannia Industries Results Update
Britannia reported Q2 consolidated sales of Rs 5,542 Crore (up 16.6%) and net profit of Rs 726 Crore (up 10.8%). Six-month sales reached Rs 10,506 Crore with profit at Rs 1,319 Crore.
Kalpataru Projects International Results Update
KPIL reported record Q2 FY27 revenue of ₹7,004 Crore and PBT up 24% YoY to ₹398 Crore. Net debt fell to ₹72 Crore, with an order book of ₹71,846 Crore.
- Order book
- ₹71,846 Cr
Fortis Healthcare Results Update
Fortis Healthcare released a press release on Q2 FY27 results, with consolidated revenue of INR 2,735 Cr up 17.3%. It also disclosed the Suguna Hospital acquisition and a 400+ bed Delhi hospital services agreement.
- hospital beds acquired
- 110.0 beds
TCPL Packaging Results Update
TCPL Packaging reported strong Q2 FY27 results, with consolidated PAT up 58% year on year. It also incorporated a battery separator film subsidiary.
Venus Pipes & Tubes Results Update
Venus Pipes' results press release showed Q2 FY27 revenue up 23.9% to Rs.361.1 Crore. EBITDA margin eased to 14.3% amid freight and fuel costs.